Dolastatin 10 has been extensively studied for its potential applications in cancer therapy due to its potent antitumor properties. It functions as a microtubule inhibitor, disrupting the formation of the mitotic spindle during cell division, which leads to the arrest of cell cycle progression and ultimately induces apoptosis in cancer cells. This mechanism makes it particularly effective against rapidly dividing tumor cells. Although Dolastatin 10 itself has not been widely adopted as a standalone therapeutic agent in clinical practice, its derivatives, such as monomethyl auristatin E (MMAE), have been successfully incorporated into antibody-drug conjugates (ADCs). These ADCs target specific cancer cells with high precision, minimizing damage to healthy tissues and improving the efficacy of cancer treatments. Dolastatin 10's role in the development of these advanced therapies highlights its significance in the field of oncology and targeted drug delivery.